Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease

MacLeod, Alison Murray; Campbell, Marion K; Cody, June D; Daly, Conal; Grant, Adrian; Khan, Izhar; Rabindranath, Kannaiyan S; Vale, Luke; Wallace, S

doi:10.1002/14651858.cd003234.pub2

Cited by 42 publications

(25 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although there is no definitive evidence to support the use of synthetic (biocompatible), high-flux membranes rather than the non-synthetic, cellulose type, 38 there may be benefits due to reduced progression of ␤2M-related dialysis amyloidosis, 39 improved systolic cardiac function, 40 prevention of the development of lipoprotein abnormalities 41 and reduction in intra-dialytic symptoms. 42 Synthetic membranes are expensive and financial constraints play a significant role in dictating the type used.…”

Section: Membrane Use (Clinical Questionnaire)mentioning

confidence: 99%

An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales

Roderick

Nicholson²,

Armitage³

et al. 2005

Health Technol Assess

100

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA Programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, ...

show abstract

Section: Membrane Use (Clinical Questionnaire)mentioning

confidence: 99%

An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales

Roderick

Nicholson²,

Armitage³

et al. 2005

Health Technol Assess

100

View full text Add to dashboard Cite

show abstract

“…2 The high morbidity and mortality of maintenance hemodialysis (MHD) patients commonly were regarded as a result of dialysis membranes bio-incapability. However, in a recent Cochrane review on this subject, 3 no evidence of benefit was found when biocompatible membranes were compared with cellulose/modified cellulose membranes in terms of reduced mortality or reduction in dialysis-related adverse symptoms. So it became apparent that not all adverse reactions during HD were solely due to dialyzer membrane composition, and that dialyzer design, membrane flux, anticoagulation with unfractionated heparins, dialysate water impurities, composition, and sterilants, such as ethylene oxide, could all cause sudden adverse effects during dialysis.…”

Section: Introductionmentioning

confidence: 99%

Differences in Bio-incompatibility among Four Biocompatible Dialyzer Membranes Using in Maintenance Hemodialysis Patients

et al. 2011

View full text Add to dashboard Cite

Background: Following the introduction of modified cellulosic and then synthetic membrane dialyzers, it was realized that the dialyzer bio-incompatibility depends on the membrane composition. We designed a prospective, randomized, cohort study of 6 months to determine several parameters of biocompatibility in maintenance hemodialysis (MHD) patients treated with four different membrane dialyzers. Methods: There were 60 MHD patients enrolled in the study. In baseline, synthetic low-flux dialyzer, polysulfone (PS) membrane was used in all patients for at least 3 months. Then the patients were randomly divided into three groups according to different dialyzer membranes. Synthetic highflux dialyzer group, ployethersulfone membrane, cellulose triacetate (CTA) high-flux membrane, and synthetic low-flux dialyzer, polymethylmethacrylate (PMMA) membrane were used in 6 months. A new dialyzer was used for each study treatment, and there was no dialyzer reuse. The biocompatibility markers and solutes removal markers were detected repeatedly at different time points. Results: The blood levels of highly sensitive C reactive protein, interleukin (IL)-1β, and interleukin (IL)-13 showed no difference among different groups at al time points. However, the blood complement levels and white blood cell counts were significantly different among three groups. When the dialyzers changed from PS to PMMA membrane, C3a levels and white blood cell counts changed significantly (p < 0.05). Moreover, the changes of C5a levels were significantly different between group CTA and group PMMA in month 3 (p < 0.05). Conclusion: There were much more differences on bio-incompatibility among different dialyzer membranes.

show abstract

“…Whereas a recent overview suggested some benefit of biocompatibility (not flux) on the clinical outcome of chronic HD patients [36] , a recent meta-analysis did not find any advantage of either biocompatibility or flux [37] . Moreover, the only prospective randomized trial comparing low-flux with high-flux dialyzers showed no major differences in the clinical outcome between the two modalities [38] .…”

Section: Discussionmentioning

confidence: 91%

Plasma Dimethylarginine Levels in Chronic Hemodialysis Patients Are Independent of the Type of Dialyzer Applied

Grooteman

Wauters

Teerlink³

et al. 2007

Blood Purif

View full text Add to dashboard Cite

Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease

Cited by 42 publications

References 98 publications

An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales

An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales

Differences in Bio-incompatibility among Four Biocompatible Dialyzer Membranes Using in Maintenance Hemodialysis Patients

Plasma Dimethylarginine Levels in Chronic Hemodialysis Patients Are Independent of the Type of Dialyzer Applied

Contact Info

Product

Resources

About